Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 8 Neoplasms 2 Recurrence 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Neuroblastoma 1 Neoplasm Metastasis 1 Granulosa Cell Tumor 1 Glioma 1 Glioblastoma 1 Genetic Diseases, Inborn 1 Castration-resistant Prostate Cancer 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Dexamethasone 29 Cyclophosphamide 21 Rituximab 17 Cytarabine 16 Bortezomib 13 Gemcitabine 12 fludarabine 11 Methotrexate 11 Lenalidomide 10 Filgrastim 10 Vincristine 9 Etoposide 9 pomalidomide 8 pembrolizumab 8 Paclitaxel 8 Azacitidine 8 venetoclax 7 carfilzomib 7 Doxorubicin 7 Docetaxel 7 Cyclosporine 7 Calcium Dobesilate 7 Antilymphocyte Serum 7 fludarabine phosphate 6 Topotecan 6 Temozolomide 6 Radiotherapy 6 Peripheral Blood Stem Cell Transplantation 6 Mitoxantrone 6 daratumumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Recurrence × Ketoconazole × Clear all

NCT02163356 2022-03-31

SPOC2013-001

South Plains Oncology Consortium

Phase 1 Terminated

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡